The University of Chicago Header Logo

Connection

Luciana Molinero to Humans

Back to Details
This is a "connection" page, showing publications Luciana Molinero has written about Humans.
Luciana Molinero
Connection Strength
0.342
Humans
  1. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. Appl Immunohistochem Mol Morphol. 2021 04 01; 29(4):258-264.
    View in: PubMed
    Score: 0.025
  2. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019 10 23; 7(1):274.
    View in: PubMed
    Score: 0.023
  3. Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus Nab-Paclitaxel for Metastatic Breast Cancer-In Reply. JAMA Oncol. 2019 06 01; 5(6):908-909.
    View in: PubMed
    Score: 0.022
  4. Basal NF-?B controls IL-7 responsiveness of quiescent naïve T cells. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7397-402.
    View in: PubMed
    Score: 0.015
  5. Role of T cell-nuclear factor ?B in transplantation. Transplant Rev (Orlando). 2012 Jul; 26(3):189-200.
    View in: PubMed
    Score: 0.013
  6. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol. 2008 Apr 01; 180(7):4606-14.
    View in: PubMed
    Score: 0.010
  7. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem. 2004 Dec; 267(1-2):177-85.
    View in: PubMed
    Score: 0.008
  8. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). Int J Gynecol Cancer. 2024 Aug 05; 34(8):1140-1148.
    View in: PubMed
    Score: 0.008
  9. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024 Sep; 131(5):820-831.
    View in: PubMed
    Score: 0.008
  10. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024 07; 186:17-25.
    View in: PubMed
    Score: 0.008
  11. Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. J Pathol. 2024 06; 263(2):190-202.
    View in: PubMed
    Score: 0.008
  12. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 10; 177:20-31.
    View in: PubMed
    Score: 0.007
  13. Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol. 2003 Jun; 73(6):815-22.
    View in: PubMed
    Score: 0.007
  14. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clin Cancer Res. 2023 05 01; 29(9):1698-1707.
    View in: PubMed
    Score: 0.007
  15. Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. Clin Immunol. 2003 Jan; 106(1):50-4.
    View in: PubMed
    Score: 0.007
  16. Codominant expression of the polymorphic MICA alloantigens encoded by genes in the HLA region. Eur J Immunogenet. 2002 Aug; 29(4):315-9.
    View in: PubMed
    Score: 0.007
  17. Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol. 2002 May; 71(5):791-7.
    View in: PubMed
    Score: 0.007
  18. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1733-1743.
    View in: PubMed
    Score: 0.007
  19. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut. 2022 07; 71(7):1277-1288.
    View in: PubMed
    Score: 0.006
  20. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021 08 02; 113(8):1005-1016.
    View in: PubMed
    Score: 0.006
  21. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 08; 32(8):983-993.
    View in: PubMed
    Score: 0.006
  22. Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021 06 25; 12(1):3969.
    View in: PubMed
    Score: 0.006
  23. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clin Breast Cancer. 2021 12; 21(6):539-551.
    View in: PubMed
    Score: 0.006
  24. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 06 10; 39(17):1842-1855.
    View in: PubMed
    Score: 0.006
  25. Enrichment of circulating tumor-derived extracellular vesicles from human plasma. J Immunol Methods. 2021 03; 490:112936.
    View in: PubMed
    Score: 0.006
  26. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 10 10; 396(10257):1090-1100.
    View in: PubMed
    Score: 0.006
  27. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21):5631-5637.
    View in: PubMed
    Score: 0.006
  28. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4.
    View in: PubMed
    Score: 0.006
  29. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
    View in: PubMed
    Score: 0.006
  30. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin Cancer Res. 2019 10 15; 25(20):6061-6072.
    View in: PubMed
    Score: 0.006
  31. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
    View in: PubMed
    Score: 0.006
  32. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2019 03 01; 5(3):334-342.
    View in: PubMed
    Score: 0.005
  33. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82.
    View in: PubMed
    Score: 0.005
  34. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018 11 01; 29(11):2247-2253.
    View in: PubMed
    Score: 0.005
  35. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 11 29; 379(22):2108-2121.
    View in: PubMed
    Score: 0.005
  36. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2019 02; 105(2):486-495.
    View in: PubMed
    Score: 0.005
  37. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018 Nov; 140(2):317-328.
    View in: PubMed
    Score: 0.005
  38. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 01; 23(17):5238-5245.
    View in: PubMed
    Score: 0.005
  39. Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers. PLoS One. 2016; 11(11):e0165856.
    View in: PubMed
    Score: 0.005
  40. Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
    View in: PubMed
    Score: 0.004
  41. ß-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci Transl Med. 2014 Feb 26; 6(225):225ra28.
    View in: PubMed
    Score: 0.004
  42. Nuclear factor (NF)-?B controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol Immunol. 2011 Sep; 48(15-16):1940-9.
    View in: PubMed
    Score: 0.003
  43. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation. 2010 Sep 15; 90(5):540-6.
    View in: PubMed
    Score: 0.003
  44. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res. 2008 Jul 15; 68(14):5778-84.
    View in: PubMed
    Score: 0.003
  45. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol. 2006 Mar; 67(3):170-82.
    View in: PubMed
    Score: 0.002
  46. NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol. 2004 Nov 01; 173(9):5583-90.
    View in: PubMed
    Score: 0.002
  47. Cloning, expression and interaction of human T-cell receptors with the bacterial superantigen SSA. Eur J Biochem. 2004 Oct; 271(20):4075-83.
    View in: PubMed
    Score: 0.002
  48. Osmotic stress sensitizes naturally resistant cells to TNF-alpha-induced apoptosis. Cell Death Differ. 2002 Oct; 9(10):1090-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.